Zepbound vs Mounjaro: one molecule, two labels, and why the label sets your price

Lilly settles the pharmacology question itself, in five words, on Mounjaro's own website: "Mounjaro is not a weight loss drug."¹ It is tirzepatide. So is Zepbound. The molecule does not know which box it was packed in, but everything else about your treatment does, and that is what this comparison is really about.

What each box is approved for

Mounjaro arrived first, in 2022, as a diabetes drug. Its approved uses are for people with type 2 diabetes: to improve blood sugar, in adults and now children from age 10, and to reduce the risk of heart attack and stroke in diabetic adults at high risk.¹ Lilly's site reports that people in its diabetes trials lost between 12 lb at 5 mg and 25 lb at 15 mg, and then states, in bold, that weight loss is not what it is for.¹

Zepbound is the same molecule resubmitted in 2023 for the thing Mounjaro was visibly doing anyway: "to reduce excess body weight and maintain weight reduction long term in adults with obesity" or overweight with a related condition, and, since 2024, for obstructive sleep apnoea in adults with obesity.²

The doses are identical

Unlike Wegovy and Ozempic, where the weight box climbs higher than the diabetes box, Zepbound and Mounjaro share the same ladder exactly. Both start at 2.5 mg for four weeks, both climb in 2.5 mg steps every four weeks, both top out at 15 mg.² The starting dose is a starting dose on both, not one you stay on. What a person on Mounjaro takes and what a person on Zepbound takes can be, milligram for milligram, the same injection.

That is what makes this pair the cleanest illustration in the category of a drug priced by its label rather than by what is in it.

What each costs, cash

Here the two boxes are not the same, and the gap is large.

Zepbound has a published self-pay programme. Lilly sells it direct to cash patients as a vial or KwikPen at $299 (2.5 mg), $399 (5 mg), $499 (7.5 mg) and $699 (10, 12.5 and 15 mg) a month.⁴ Every dose is priced in Zepbound without insurance.

Mounjaro has no equivalent. Lilly's pricing page gives its list price, "$1,112.16 per fill", and then says that people without coverage "may be eligible for self-pay savings options", with terms and conditions and no number.³ That is a materially different offer from a published price, and it means the same tirzepatide in the diabetes box has no reliable cash price at all.

What each costs through a plan

The mirror image. Mounjaro is a diabetes drug, so a plan that covers diabetes medicines covers it, and Lilly's card takes commercially insured patients to $25 for up to three months.⁵ Prescribed for weight loss, the same pen is refused by nearly every insurer, because the prescription does not match the formulary's reason for listing it.

Zepbound is the box a plan can cover for weight, and whether yours does is plan-specific. Here is the position of eight insurers, quoted from their own documents:

Every one of the eight says no to Mounjaro for weight loss. For Zepbound the answers range from covered (TRICARE) to excluded (Humana) with "depends on your plan" in between. If you have type 2 diabetes, Mounjaro is the easy prescription and the well-covered one. If you do not, Zepbound is the only box that can be covered at all, and the coverage guide is the order to ask in.

The third box, again

Because both are one molecule, the cheap route is one molecule too. Licensed compounding pharmacies sell tirzepatide through telehealth programs, not FDA-approved as a finished product, at prices that make Lilly's $699 look like the list price it replaced. Today, from every seller we track, verified on each seller's own page:

From $119 a month. That is the same molecule as both branded boxes at a sixth of the maintenance price, with the loss of FDA review as the trade. Check the seller first; the gap is wide enough to attract the wrong kind of pharmacy as well as the right kind.

Choosing the box

• Type 2 diabetes: Mounjaro. It is approved for you, widely covered, and the card brings it to $25. The weight loss comes with it.
• Weight loss, insured: Zepbound. Mounjaro on a weight prescription will be refused.
• Weight loss, paying cash: Zepbound self-pay, $299 to $699, because Mounjaro has no published cash price. Or compounded tirzepatide from $119 with the trade-off above.
• Sleep apnoea with obesity: Zepbound is the only one approved for it, which is also a coverage lever with some plans.

The honest summary

There is nothing to choose between Zepbound and Mounjaro as drugs. There is everything to choose between them as products. The label decides whether a plan pays, and it decides whether a published cash price exists at all. Match the box to the reason on your prescription, and if the reason is weight and the plan says no, the compounded version of the same molecule is the route most cash payers take.